• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sarah Faulkner

FDA publishes finalized guidance for buprenorphine depots

February 7, 2019 By Sarah Faulkner

FDA-logo-new

The FDA this week published a finalized guidance document for companies developing new buprenorphine depot products for the treatment of opioid use disorder. The agency is hoping to boost the development of modified-release buprenorphine products, like drug-eluting implants. In the document, the FDA detailed the studies needed to support approval for these products through the 505(b)(2) […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: FDA

Flowonix wins FDA nod for infusion pump software

February 6, 2019 By Sarah Faulkner

Flowonix pump software

Flowonix Medical said yesterday that it won FDA approval to market the updated software used to program the company’s Prometra infusion system. The clinician programmer software, which Flowonix plans to launch in February, includes automatic calculations and increased dosing flexibility during bridge bolusing, according to the company. Flowonix’s programmable Prometra pump is indicated for intrathecal […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Flowonix, Flowonix Medical

Study: Use of long-acting reversible contraception spiked after 2016 election

February 6, 2019 By Sarah Faulkner

In a study published this week in JAMA Internal Medicine, researchers reported that use of long-acting reversible contraception increased in the month following the 2016 presidential election. Adjusting for seasonal trends and patient characteristics, the researchers from Brigham & Women’s Hospital found that insertion of contraceptives such as intrauterine devices increased by 21.6% after the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Women's Health Tagged With: Brigham & Women's Hospital

Audion touts Ph1 results for hearing loss drug

February 6, 2019 By Sarah Faulkner

Audion Therapeutics logo

Audion Therapeutics touted positive results yesterday from a Phase I trial of the company’s hearing loss drug. In 15 people with mild to moderate sensorineural hearing loss, Audion tested the safety and tolerability of its LY3056480 mediated Notch inhibitor. The drug is designed to regenerate the inner ear sensory hair cells that are lost over […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: audiontherapeutics

FDA doubles down on warfarin test strip recall

February 5, 2019 By Sarah Faulkner

FDA-logo-new

The FDA this week alerted patients and doctors about test strips used to monitor levels of the blood thinner warfarin, expanding and reiterating its warning that the products shouldn’t be used to adjust a person’s drug dosage. The agency’s latest notice is related to the Class I recall of Roche‘s CoaguChek meters and test strips, […]

Filed Under: Diagnostics, Featured, Pharmaceuticals, Regulatory/Compliance, Vascular Tagged With: rochediagnostics

Reva Medical cuts 44% of workforce

February 5, 2019 By Sarah Faulkner

Reva Medical updated logo

Reva Medical (ASX:RVA) said this week that it plans to cut its workforce by 44%, leaving 22 employees at the San Deigo-based company. In a statement, Reva CEO Reggie Groves cited current market conditions as the primary reason for the staffing reduction. “While we continue to see strong interest in Fantom Encore and are excited about […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Lyndra raises $55m for long-acting drug delivery capsule

January 29, 2019 By Sarah Faulkner

Lyndra updated

Lyndra Therapeutics said today that it raised $55 million in a Series B round to support the development of its oral drug delivery system. All of the investors from the company’s $23 million Series A round resubscribed for the Series B round, Lyndra reported. New investors included the Bill & Melinda Gates Foundation. Lyndra’s oral […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: lyndra

BioCorRx wins $5.6m grant for sustained release naltrexone implant

January 28, 2019 By Sarah Faulkner

BioCorRx updated logo

BioCorRx (OTC:BICX) announced this month that it won a two-year grant from the NIH’s National Institute on Drug Abuse to support the development of its sustained release naltrexone implant for the treatment of opioid use disorder. The grant includes $2.8 million for Feb. 1, 2019 to Jan. 31, 2020, followed by $2.8 million for the second […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals, Wall Street Beat Tagged With: BioCorRx, National Institutes of Health

BTG touts use of radiopaque drug-eluting bead

January 28, 2019 By Sarah Faulkner

BTG's Interventional Oncology Logo

BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead. The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG. The beads’ radiopacity enable […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: BTG

Circassia inks exclusive ventilator commercialization deal with AIT Therapeutics

January 28, 2019 By Sarah Faulkner

Circassia Pharmaceuticals logo

Circassia Pharmaceuticals said last week that it inked a deal for the exclusive commercialization rights to AIT Therapeutics’ nitric oxide device, AirNOvent, in the U.S. and China. Using an electric voltage, the portable AirNOvent system produces nitric oxide from the nitrogen and oxygen in the air. According to the terms of the deal, Circassia is […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: circassiapharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Interim pages omitted …
  • Page 241
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS